Welcure Drugs & Pharmaceuticals Ltd Share Price

6.99
(4.95%)
Jul 22, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open6.9
  • Day's High6.99
  • 52 Wk High6.99
  • Prev. Close6.66
  • Day's Low6.9
  • 52 Wk Low3.2
  • Turnover (lac)29.39
  • P/E0
  • Face Value10
  • Book Value1.04
  • EPS0
  • Mkt. Cap (Cr.)9.44
  • Div. Yield0
No Records Found

Welcure Drugs & Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

6.9

Prev. Close

6.66

Turnover(Lac.)

29.39

Day's High

6.99

Day's Low

6.9

52 Week's High

6.99

52 Week's Low

3.2

Book Value

1.04

Face Value

10

Mkt Cap (₹ Cr.)

9.44

P/E

0

EPS

0

Divi. Yield

0

Welcure Drugs & Pharmaceuticals Ltd Corporate Action

18 Jul 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

4 Sep 2023

12:00 AM

AGM

Announcement Date: 04 Sep, 2023

arrow

20 Sep 2023

12:00 AM

BookCloser

arrow

Welcure Drugs & Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Welcure Drugs & Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

25 Jul, 2024|08:48 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 0.00%

Foreign: 0.00%

Indian: 0.00%

Non-Promoter- 1000.00%

Institutions: 0.00%

Non-Institutions: 100.00%

Custodian: 0.00%

Share Price

Welcure Drugs & Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

13.44

12.12

12.12

12.12

Preference Capital

0

0

0

0

Reserves

-11.92

-12.03

-12.05

-12.1

Net Worth

1.52

0.08

0.06

0.01

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

0.1

0.13

0.08

0.05

yoy growth (%)

-21.23

61.57

65

-44.19

Raw materials

0

0

0

0

As % of sales

0

0

0

0

Employee costs

-0.01

0

0

0

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

0.02

0.05

0

-0.01

Depreciation

0

0

0

0

Tax paid

0

0

0

0

Working capital

0.02

0.03

-0.01

-0.02

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-21.23

61.57

65

-44.19

Op profit growth

-57.05

-661.27

-52.28

-174.27

EBIT growth

-57.2

-684.21

-51.13

-169.92

Net profit growth

-57.2

-684.21

-51.13

-169.92

View Ratios

No Record found

Welcure Drugs & Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,619.75

127.343,88,632.28867.60.835,536.9998.75

Cipla Ltd

CIPLA

1,503.9

32.691,21,442.631,038.40.563,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,547.35

76.631,20,717.855310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,179.45

34.531,18,680.271,405.20.253,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,817.15

26.551,13,730.311,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Welcure Drugs & Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Non-Exec. & Independent Dir.

Gagan Juneja

Independent Director

Mohd. Shahbaz Alam

Additional Director

Sitaben S Patel

Additional Director

Rajeev Mehra

Managing Director

Vishal Mehra

Company Sec. & Compli. Officer

Manowar Ali

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Reports by Welcure Drugs & Pharmaceuticals Ltd

Summary

Incorporated on 4 Jun.92, Welcure Drugs And Pharmaceuticals (WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain. The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc. WDPL had come out with a Rs 4-cr public issue in Aug.94 to part-finance the Rs 7-cr project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL). The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.96 to finance its expansion programmes.Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations. It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen. It manufactures over a hundred varieties of tablets, capsules and dry syrups, sulpha drugs, vitamins, analgesics, etc. Its subsidiary, AKL, manufactures 6-APA, a key drug intermediate in the manufacture of semi-synthetic penicillin. The company has decided to set up new sections of paediatrics and veterinary drugs and to diversify into ointments and liquid syrups. The new products of the company WELSTAP , X- CLOX , ETHAMBUTOL, RIFA- Z , CETIRIZIN , NORTIN have been well accepted in the market.The Company has entered into a collaboration agreement with a russian company to act as their sole selling agent for a unique medicine Stevioside, an alternate to sugar, S
Read More

Company FAQs

What is the Welcure Drugs & Pharmaceuticals Ltd share price today?

Down Arrow

The Welcure Drugs & Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹6.99 today.

What is the Market Cap of Welcure Drugs & Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Welcure Drugs & Pharmaceuticals Ltd is ₹9.44 Cr. as of 22 Jul ‘24

What is the PE and PB ratio of Welcure Drugs & Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Welcure Drugs & Pharmaceuticals Ltd is 0 and 6.70 as of 22 Jul ‘24

What is the 52 Week High and Low of Welcure Drugs & Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Welcure Drugs & Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Welcure Drugs & Pharmaceuticals Ltd is ₹3.2 and ₹6.99 as of 22 Jul ‘24

What is the CAGR of Welcure Drugs & Pharmaceuticals Ltd?

Down Arrow

Welcure Drugs & Pharmaceuticals Ltd's CAGR for 5 Years at 69.47%, 3 Years at 7.61%, 1 Year at 86.40%, 6 Month at 62.56%, 3 Month at 51.30% and 1 Month at 40.36%.

What is the shareholding pattern of Welcure Drugs & Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Welcure Drugs & Pharmaceuticals Ltd is as follows:
Promoters - 0.00 %
Institutions - 0.00 %
Public - 100.00 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.